However, this strategy might be further optimized, because both ABT-199 and Mcl-1 inhibitors are BH3 mimetics that antagonize antiapoptotic proteins of the Bcl-2 family but do not affect the expression of BH3-only proteins in AML cells21. The gene discussed is BCL2; the disease is acute myeloid leukemia.